BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 5, 2023
See today's BioWorld
Home
» CBO’s H.R. 3 forecast not so sunny for U.S. drug innovation
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
CBO’s H.R. 3 forecast not so sunny for U.S. drug innovation
Aug. 30, 2021
By
Mari Serebrov
No Comments
Sure H.R. 3 could save the U.S. government hundreds of billions of dollars on drug spending, but that savings comes at a long-term cost in innovation that’s higher than the Congressional Budget Office (CBO) initially forecast.
BioWorld
Regulatory
Biosimilar
U.S.